These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 12168868)

  • 1. Immunohistochemical study of the expression of S-100 protein, epithelial membrane antigen, cytokeratin and carcinoembryonic antigen in thyroid lesions.
    Mitselou A; Vougiouklakis TG; Peschos D; Dallas P; Boumba VA; Agnantis NJ
    Anticancer Res; 2002; 22(3):1777-80. PubMed ID: 12168868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epithelial membrane antigen and S-100 protein expression in benign and malignant papillary thyroid neoplasms.
    Kilicarslan B; Pesterelli EH; Oren N; Sargin FC; Karpuzoglu G
    Adv Clin Path; 2000 Oct; 4(4):155-8. PubMed ID: 11436147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immunohistochemical localization of S100 in the diagnosis of papillary carcinoma of the thyroid.
    McLaren KM; Cossar DW
    Hum Pathol; 1996 Jul; 27(7):633-6. PubMed ID: 8698304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-molecular-weight cytokeratin and cytokeratin-19 in the diagnosis of thyroid tumors.
    Raphael SJ; McKeown-Eyssen G; Asa SL
    Mod Pathol; 1994 Apr; 7(3):295-300. PubMed ID: 7520169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid.
    Rossi ED; Raffaelli M; Mule' A; Miraglia A; Lombardi CP; Vecchio FM; Fadda G
    Histopathology; 2006 Jun; 48(7):795-800. PubMed ID: 16722927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p27kip1 expression distinguishes papillary hyperplasia in Graves' disease from papillary thyroid carcinoma.
    Erickson LA; Yousef OM; Jin L; Lohse CM; Pankratz VS; Lloyd RV
    Mod Pathol; 2000 Sep; 13(9):1014-9. PubMed ID: 11007042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Solid papillary ductal carcinoma in situ versus usual ductal hyperplasia in the breast: a potentially difficult distinction resolved by cytokeratin 5/6.
    Rabban JT; Koerner FC; Lerwill MF
    Hum Pathol; 2006 Jul; 37(7):787-93. PubMed ID: 16784976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The expression and role of serum response factor in papillary carcinoma of the thyroid.
    Kim HJ; Kim KR; Park HS; Jang KY; Chung MJ; Shong M; Moon WS
    Int J Oncol; 2009 Jul; 35(1):49-55. PubMed ID: 19513551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cribriform-morular variant of papillary carcinoma: the sporadic counterpart of familial adenomatous polyposis-associated thyroid carcinoma. A case report with clinical and molecular genetic correlation.
    Ng SB; Sittampalam K; Goh YH; Eu KW
    Pathology; 2003 Feb; 35(1):42-6. PubMed ID: 12701683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p63 expression in solid cell nests of the thyroid: further evidence for a stem cell origin.
    Reis-Filho JS; Preto A; Soares P; Ricardo S; Cameselle-Teijeiro J; Sobrinho-Simões M
    Mod Pathol; 2003 Jan; 16(1):43-8. PubMed ID: 12527712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunohistochemical analysis of malignant tumors of the thyroid gland using 6 relevant markers].
    Brasanac D; Jancić-Zgurics M; Janković R; Tatić S
    Srp Arh Celok Lek; 1993; 121(3-7):70-3. PubMed ID: 7716641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma: a note of caution.
    Sahoo S; Hoda SA; Rosai J; DeLellis RA
    Am J Clin Pathol; 2001 Nov; 116(5):696-702. PubMed ID: 11710686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1.
    Casey MB; Lohse CM; Lloyd RV
    Endocr Pathol; 2003; 14(1):55-60. PubMed ID: 12746563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic utility of CD56 immunohistochemistry in papillary carcinoma of the thyroid.
    El Demellawy D; Nasr AL; Babay S; Alowami S
    Pathol Res Pract; 2009; 205(5):303-9. PubMed ID: 19153015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hashimoto's thyroiditis with papillary thyroid carcinoma (PTC)-like nuclear alterations express molecular markers of PTC.
    Prasad ML; Huang Y; Pellegata NS; de la Chapelle A; Kloos RT
    Histopathology; 2004 Jul; 45(1):39-46. PubMed ID: 15228442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of the MUC1 and MUC4 expressions in thyroid papillary carcinoma.
    Baek SK; Woo JS; Kwon SY; Lee SH; Chae YS; Jung KY
    Laryngoscope; 2007 May; 117(5):911-6. PubMed ID: 17473695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Detection of cytokeratin 19 and thyroperoxidase expressions in the diagnosis of thyroid diseases].
    Yang QX; Shao CK; Feng ZY; Huang BQ; Han AJ; Xiong M; Zhao WL; Wu TT
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Jun; 25(6):678-81. PubMed ID: 15958307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An immunohistochemical study in thyroid cancer.
    Beltrami CA; Barbatelli G; Criante P; Paliaga A; Amadi CE
    Appl Pathol; 1987; 5(4):229-45. PubMed ID: 2446641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical expression of pl30cas in papillary thyroid carcinoma.
    Dilek FH; Aktepe F; Sahin DA; Topak N; Dilek ON
    Int Surg; 2008; 93(3):175-80. PubMed ID: 18828274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical expression of cyclin D1, E2F-1, and Ki-67 in benign and malignant thyroid lesions.
    Saiz AD; Olvera M; Rezk S; Florentine BA; McCourty A; Brynes RK
    J Pathol; 2002 Oct; 198(2):157-62. PubMed ID: 12237874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.